Literature DB >> 34031014

Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us.

Geniver El Tekle1, Tiziano Bernasocchi1, Arun M Unni2, Francesco Bertoni1, Davide Rossi3, Mark A Rubin4, Jean-Philippe Theurillat5.   

Abstract

Cancer is the dysregulated proliferation of cells caused by acquired mutations in key driver genes. The most frequently mutated driver genes promote tumorigenesis in various organisms, cell types, and genetic backgrounds. However, recent cancer genomics studies also point to the existence of context-dependent driver gene functions, where specific mutations occur predominately or even exclusively in certain tumor types or genetic backgrounds. Here, we review examples of co-occurring and mutually exclusive driver gene mutation patterns across cancer genomes and discuss their underlying biology. While co-occurring driver genes typically activate collaborating oncogenic pathways, we identify two distinct biological categories of incompatibilities among the mutually exclusive driver genes depending on whether the mutated drivers trigger the same or divergent tumorigenic pathways. Finally, we discuss possible therapeutic avenues emerging from the study of incompatible driver gene mutations.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer driver mutations; co-occurrence; driver genes antagonism; genomic patterns; mutual exclusivity; pathway redundancy and divergence; synergy; synthetic essentiality; synthetic lethality

Mesh:

Year:  2021        PMID: 34031014     DOI: 10.1016/j.trecan.2021.04.009

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  7 in total

1.  Clinical and genomic features of SPOP-mutant prostate cancer.

Authors:  Mari Nakazawa; Mike Fang; Catherine H Marshall; Tamara L Lotan; Pedro Isaacsson Velho; Emmanuel S Antonarakis
Journal:  Prostate       Date:  2021-11-15       Impact factor: 4.104

2.  RAB42 is a Potential Biomarker that Correlates With Immune Infiltration in Hepatocellular Carcinoma.

Authors:  Hao Peng; Xuanlong Du; Yewei Zhang
Journal:  Front Mol Biosci       Date:  2022-05-26

3.  Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer.

Authors:  Zheqi Li; Nicole S Spoelstra; Matthew J Sikora; Sharon B Sams; Anthony Elias; Jennifer K Richer; Adrian V Lee; Steffi Oesterreich
Journal:  NPJ Breast Cancer       Date:  2022-05-10

Review 4.  Metabolic Rewiring in Glioblastoma Cancer: EGFR, IDH and Beyond.

Authors:  Abdellatif El Khayari; Najat Bouchmaa; Bouchra Taib; Zhiyun Wei; Ailiang Zeng; Rachid El Fatimy
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

5.  A Pan-Cancer Assessment of RB1/TP53 Co-Mutations.

Authors:  Ling Cai; Ralph J DeBerardinis; Guanghua Xiao; John D Minna; Yang Xie
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

6.  RAB6B is a potential prognostic marker and correlated with the remolding of tumor immune microenvironment in hepatocellular carcinoma.

Authors:  Hao Peng; Erwei Zhu; Jitao Wang; Xuanlong Du; Chonggao Wang; Meng Yang; Yewei Zhang
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

Review 7.  Big data in basic and translational cancer research.

Authors:  Peng Jiang; Sanju Sinha; Kenneth Aldape; Sridhar Hannenhalli; Cenk Sahinalp; Eytan Ruppin
Journal:  Nat Rev Cancer       Date:  2022-09-05       Impact factor: 69.800

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.